Yang, Hwai-I 楊懷壹

YangHI6x7 副研究員

hiyang

02-27871308

EDUCATION AND POSITIONS HELD:

Ph.D., Graduate Institute of Epidemiology, School of Public Health, National Taiwan University, Taipei, Taiwan, 2006
Postdoctoral Fellow, Genomics Research Center, Academia Sinica, Taipei, Taiwan, 2006- 2011
Associate Professor, Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan, 2011 - 2013
Associate Research Fellow, Molecular and Genomic Epidemiology Center (MaGEC), China Medical University Hospital, Taichung, Taiwan, 2011 - 2013
Associate Professor, Genomics Research Center, Academia Sinica, Taipei, Taiwan, 2012 - present
Adjunct Associate Professor, Graduate Institute of Clinical Medicine, National Yang-Ming University, 2014 – present
Deputy Director, Genomics Research Center, Academia Sinica, 2019-2023

HONORS:

Prof. K-P Chen Award for the Best Public Health Paper, Taiwan Public Health Association, 2004
Honorary Member, Phi Tau Phi Scholastic Honor Society, 2006
Distinguished Postdoctoral Scholar of Academia Sinica, 2007-2008
The 20th Wang Ming-Ning Award (as a member of the REVEAL-HBV study group led by Prof. Chien-Jen Chen), 2010
Ta-You Wu Memorial Award, National Science Council, Taiwan, 2013
The 2013 Award for Outstanding Contributions in Science and Technology, Executive Yuan (co-awardee: Prof. Chien-Jen Chen and Dr. Mei-Hsuan Lee), 2013

RESEARCH INTERESTS:

1. Epidemiology of viral hepatitis:

Conducting longitudinal studies to delineate the incidence and determinants (including viral, host, and environmental factors) of milestone transitions and disease progression in the natural history of chronic hepatitis B and C.
Recently, the focus has been on employing full-length deep sequencing of the hepatitis B virus to comprehend the distribution of quasispecies and variants in chronic hepatitis B patients. Investigations are underway to understand how these viral quasispecies interact with human genetic and immune factors, influencing the progression of the disease.

2. Development of risk prediction scores: Deriving and validating risk prediction tools which integrate multiple clinical parameters to predict the progression and adverse sequelae of chronic hepatitis B and C.

3. Health outcomes and high-risk groups for people with fatty liver and metabolic disorders

4. Biomarkers for early cancer detection: Exploring multi-omics pre-diagnostic biosignatures with potential for predicting major cancers.

我們主要致力於下列研究工作：

1. 了解病毒性肝炎的自然史及推動其進展的病毒、宿主和環境決定因子；近期研究重點是採用B型肝炎病毒全長深度定序來剖析慢性B型肝炎患者中病毒族群和變異的分佈，以及這些病毒準種（quasispecies）如何與人類遺傳和免疫因素相互作用，從而影響疾病的進展。

2. 開發及驗證風險預測模式，整合多個臨床參數以預測慢性B型和C型肝炎的進展和相關末期肝疾。

3. 分析脂肪肝和代謝紊亂患者的健康事件及辨識高危險族群。

4. 研究癌症的早期偵測生物指標，探索具有預測主要癌症潛力的多體學診斷前生物標記。

SELECTED PUBLICATIONS:

Lin HC, Liu J, Pan MH, Lee MH, Batrla-Utermann R, Lu SN, Jeng WJ, Yang HI*, Chen CJ, accepted, “Rapid decline rather than absolute level of HBsAg predicts its seroclearance in untreated chronic hepatitis B patients from Taiwanese communities.”, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY. (SCIE)
Hsu YC, Tseng CH, Huang YT, Yang HI, accepted, “Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective.”, Seminars in liver disease. (SCIE)
Lin HC, Jeng WJ, Liu J, Pan MH, Lee MH, Batrla-Utermann R, Lu SN, Chen CF, Yang HI*, Chen CJ, 2024, “Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients.”, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, doi: 10.1111/apt.17915, Online ahead of print. (SCIE)
Chen YJ, Hsiao TH, Lin YC, Jeng WJ, Mao CL, Wei CY, Hsieh YC, Huang CJ, Pan MH, Chen IC, Lin CH, Chen YM, Yang HI*, 2024, “Polygenic Risk Score Predicts Earlier-Onset Adult Systemic Lupus Erythematosus and First-Year Renal Diseases in a Taiwanese Cohort.”, RMD OPEN, 10(2), e003293. (SCIE)
Yang HI*, 2023, “Artificial intelligence in the prediction of progression and outcome in viral hepatitis”, editor(s): Su TH, Kao JH, Artificial Intelligence, Machine Learning, and Deep Learning in Precision Medicine in Liver Diseases, pp. 24, United Kingdom: Academic Press.
Chu YJ, Yang HI, Hu HH, Liu J, Lin YL, Chang CL, Luo WS, Jen CL, Chen CJ, 2023, “HBV genotype-dependent association of HLA variants with the serodecline of HBsAg in chronic hepatitis B patients.”, SCIENTIFIC REPORTS, 13(1), 359. (SCIE)
Hsieh YC, Pan MH, Jeng WJ, Hu HH, Liu J, Mizokami M, Chen CJ, Yang HI*, 2023, “Serum HBcrAg and hepatocellular carcinoma in a Taiwanese population seronegative for HBsAg and anti-HCV.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 21(5), 1303-1313. (SCIE)
Wu HC*, Jeng WJ, Pan MH, Hsieh YC, Lu SN, Chen CJ, Yang HI*, 2022, “Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection.”, JHEP Reports, 4(2), 100410-doi: 10.1016/j.jhepr. (SCIE)
Wen-Juei Jeng, Mei-Hung Pan, Hwai-I Yang*, 2022, “Letter: sPD‐1 as a predictor for HBsAg seroconversion—shed light on inactive carriers with chronic hepatsitis B. Authors' reply”, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 55(8), 1057-1058. (SCIE)
Huang DQ, Li X, Le MH, Le AK, Yeo YH, Trinh HN, Zhang J, Li J, Wong C, Wong C, Cheung RC, Yang HI*, Nguyen MH*, 2022, “Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients with Indeterminate Phase”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 20(8), 1803-1812. (SCIE)
Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH, 2022, “Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 20(4), 874-885. (SCIE)
Hu HH, Jeng WJ, Pan MH, Luo WS, Chang CL, Huang YT, Su CY, Chiang CT, Jen CL, Chien YC, Lu SN, Wang LY, Huang LR, Lee MH, Liu J, Nguyen MH, Chen CJ, Yang HI*, 2022, “Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B.”, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 55(5), 558-567. (SCIE)
Chu YJ, Jeng WJ, Pan MH, Hu HH, Luo WS, Su CY, Chiang CT, Jen CL, Chen CJ, Yang HI*, 2022, “Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B.”, JOURNAL OF GASTROENTEROLOGY, 57(6), 423-432. (SCIE)
Jeng Wen-Juei*, Chen Chien-Hung*, Wang Yi-Wen, Pan Mei-Hung, Lin Chia-Wei, Lin Chun-Yen, Yang Hwai-I*, 2022, “The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays”, VIROLOGY JOURNAL, 19(1), 59-10.1186/s12985-022-0. (SCIE)
Le AK, Yang HI, Yeh ML, Jin M, Trinh HN, Henry L, Liu A, Zhang JQ, Li J, Wong C, Wong C, Cheung R, Yu ML, Nguyen MH, 2021, “Development and validation of a risk score for liver cirrhosis prediction in untreated and treated chronic hepatitis B.”, JOURNAL OF INFECTIOUS DISEASES, 223(1), 139-146. (SCIE)
Yang HI*, Hsu YC, 2021, “Editorial: incorporating liver stiffness to risk scores for HCC in patients with chronic hepatitis B treated with oral antivirals: ready to use or not?”, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 53(6), 753-754. (SCIE)
Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H*, Yang HI*, 2021, “Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 19(12), 2499-2513. (SCIE)
Liu Z, Huang CJ, Huang YH, Pan MH, Lee MH, Yu KJ, Pfeiffer RM, Viard M, Yuki Y, Gao X, Carrington M, Chen CJ*, Hildesheim A*, Yang HI*, 2021, “HLA zygosity increases risk of hepatitis B virus-associated hepatocellular carcinoma.”, JOURNAL OF INFECTIOUS DISEASES, 224(10), 1796-1805. (SCIE)
Yang HI*, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH*, 2020, “Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy.”, JOURNAL OF INFECTIOUS DISEASES, 221(3):389-399. (SCIE)
Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH, 2020, “Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.”, The American Journal of Gastroenterology, 115(2), 271-280. (SCIE)
Jackson SS, Adami HO, Andreotti G, Beane-Freeman LE, Berrington de Gonzalez A, Buring JE, Fraser GE, Freedman ND, Gapstur SM, Gierach G, Giles GG, Grodstein F, Hartge P, Jenab M, Kirsh V, Knutsen SF, Lan Q, Larsson SC, Lee IM, Lee MH, Liao LM, Milne RL, Monroe KR, Neuhouser ML, O'Brien KM, Petrick JL, Purdue MP, Rohan TE, Sandin S, Sandler DP, Sawada N, Shadyab AH, Simon TG, Sinha R, Stolzenberg-Solomon R, Tsugane S, Weiderpass E, Wolk A, Yang HI, Zheng W, McGlynn KA, Campbell PT, Koshiol J, 2020, “Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project.”, JOURNAL OF HEPATOLOGY, 73(4), 863-872. (SCIE)
Liu J, Hu HH, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, Yuan Q, Xia NS, Sugiyama M, Nishida N, Mizokami M, Chen CJ, Chen PJ, Yang HI*, 2019, “Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals With Chronic Hepatitis B Virus Infection.”, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 17(7):1413-1415. (SCIE)
Kong Y, Jia J, Yang HI*, 2019, “Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.”, JAMA oncology, 5(6):915-916. (SCIE)
Lin SH, Huang YT, Yang HI, 2019, “On identification of agonistic interaction: Hepatitis B and C interaction on hepatocellular carcinoma.”, Statistics in medicine, 38(13),2467-2476. (SCIE)
Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, Kwak MS, Park YM, Fung JYY, Buti M, Rodriguez M, Treeprasertsuk S, Preda CM, Ungtrakul T, Charatcharoenwitthaya P, Li X, Li J, Zhang J, Le MH, Wei B, Zou B, Le A, Jeong D, Chien N, Kam L, Lee CC, Riveiro-Barciela M, Istratescu D, Sriprayoon T, Chong Y, Tanwandee T, Kobayashi M, Suzuki F, Yuen MF, Lee HS, Kao JH, Lok AS, Wu CY, Nguyen MH, 2019, “Factors Associated with Rates of HBsAg Seroclearance in Adults with Chronic HBV Infection: A systematic review and meta-analysis.”, Gastroenterology, 156(3):635-646. (SCIE)
Hu HH, Liu J, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, Quan Y, Xia NS, Chen CJ, Chen PJ*, Yang HI*, 2019, “Level of hepatitis B (HB) core antibody associates with seroclearance of HBV DNA and HB surface antigen in HB e antigen-seronegative patients.”, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 17(1):172-181. (SCIE)
Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, Zhang J, Wong C, Wong C, Trinh H, 2019, “Reduced Incidence of Hepatocellular Carcinoma with Tenofovir in Chronic Hepatitis B Patients with and without Cirrhosis - a Propensity Score Matched Study.”, The Journal of infectious diseases, 219(1):10-18. (SCIE)
Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF, 2019, “Taiwan consensus statement on the management of chronic hepatitis B.”, JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 118(1):7-38. (SCIE)
Wen YH, Yang HI, Chou HC, Chen CY, Hsieh WS, Tsou KI, Tsao PN, 2019, “Association of Maternal Preeclampsia with Neonatal Respiratory Distress Syndrome in Very-Low-Birth-Weight Infants.”, Scientific reports, 9(1), 13212. (SCIE)
Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH, 2019, “Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium.”, Hepatology international, 13(5), 587-598. (SCIE)
Jeng WJ, Yang HI*, 2019, “Discrepant range of sPD-1 in different studies of chronic hepatitis B. A letter in response to Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B.”, Journal of viral hepatitis, 26(7), 930. (SCIE)
Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jung Jun M, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH, Ahn SB, Azuma K, Dohmen K, Yoon Jeong J, Jung JH, Kajiwara E, Kato M, Kawano A, Koyanagi T, Ooho A, Park SH, Satoh T, Shimoda S, Song DS, Takahashi K, Yeh ML, Yoon EL, 2019, “HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication.”, Clinical Infectious Diseases, 71(11), 2840-2848. (SCIE)
Irham LM, Wong HS, Perwitasari DA, Chou WH, Yang HI*, Chang WC*, 2019, “Single-nucleotide polymorphism of rs7944135 (macrophage-expressed gene 1) is associated with hepatitis B surface antigen seroclearance in chronic hepatitis B infection: A cohort study.”, Medicine, 98(51), e17936. (SCIE)
Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH, 2019, “Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.”, The American journal of gastroenterology, 115(2), 271-280. (SCIE)
Tsai TY, Peng CY, Yang HI, Huang YL, Tao MH, Yuan SS, Lai HC, Hsieh SL, 2018, “The human C-type lectin 18 is a potential biomarker in patients with chronic hepatitis B virus infection.”, Journal of biomedical science, 25,59. (SCIE)
Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, Huang YH, Jen CL, Su CY, Nishida N, Sugiyama M, Lu SN, Wang LY, Yuan Y, L'Italien G, Yang HI, Mizokami M, Chen CJ, Lee MH, 2018, “A Glycomarker for Short-term Prediction of Hepatocellular Carcinoma: A Longitudinal Study With Serial Measurements.”, Clinical and translational gastroenterology, 9(9), 183. (SCIE)
Shih S, Huang YT, Yang HI, 2018, “A multiple mediator analysis approach to quantify the effects of the ADH1B and ALDH2 genes on hepatocellular carcinoma risk.”, Genetic epidemiology, 42(2), 394-404. (SCIE)
Chu YJ, Yang HI, Wu HC, Lee MH, Liu J, Wang LY, Lu SN, Jen CL, You SL, Santella RM, Chen CJ, 2018, “Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption.”, EUROPEAN JOURNAL OF CANCER, 94, 37-46. (SCIE)
O'Brien TR, Yang HI, Groover S, Jeng WJ, 2018, “Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression.”, Gastroenterology, 156(2)(SI), 400-417. (SCIE)
Polaris Observatory Collaborators, 2018, “Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.”, The Lancet Gastroenterology & Hepatology, 3(6), 383-403. (SCIE)
Wu HC, Yang HI, Wang Q, Chen CJ, Santella RM, 2017, “Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.”, Carcinogenesis, 38(10), 1021-1028. (SCIE)
Huang YW, Yang HI, Wu YT, Hsu TL, Lin TW, Kelly JW, Wong CH, 2017, “Residues Comprising the Enhanced Aromatic Sequon Influence Protein N-Glycosylation Efficiency.”, Journal of the American Chemical Society, 139(37), 12947-12955. (SCIE)
Pan WC, Yang HI*, 2017, “Response to RE: Fine Particle Pollution, Alanine Transaminase, and Liver Cancer: A Taiwanese Prospective Cohort Study (REVEAL-HBV)”, JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 109(1), djw185. (SCIE)
Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, Mizokami M, Chen CJ, Yang HI*, 2017, “Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.”, Scientific reports, 7(1), 14352. (SCIE)
Yang HI, Tseng TC, Liu J, Lee MH, Liu CJ, Su TH, Batrla-Utermann R, Chan HL, Kao JH, Chen CJ, 2016, “Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of HBV DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 14(3), 461-468. (SCIE)
Hoang JK, Yang HI*, Le A, Nguyen NH, Lin D, Vu VD, Chaung K, Nguyen V, Trinh HN, Li J, Zhang JQ, Chen CJ, Nguyen MH*, 2016, “Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis.”, Medicine, 95(31), e4433. (SCIE)
Chen CJ, Yang HI, Lee MH, Liu J, Hu HH, 2016, “Natural history of HBV infection in the community”, editor(s): Liaw YF, Zoulim F, Hepatitis B Virus in Human Diseases, pp. 249-276, Switzerland: Springer International Publishing Switzerland.
Chen YC*, Hsiao CJ, Jung CC, Hu HH, Chen JH, Lee WC, Chiou JM, Chen TF, Sun Y, Wen LL, Yip PK, Chu YM, Chen CJ*, Yang HI*, 2016, “Performance Metrics for Selecting Single Nucleotide Polymorphisms in Late-onset Alzheimer's Disease.”, Scientific Reports, 6, 36155. (SCIE)
Poh Z, Shen L, Yang HI, Seto WK, Wong VW, Lin CY, Goh BG, Chang PJ, Chan HL, Yuen MF, Chen CJ, Tan CK, 2016, “Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B.”, Gut, 65(5), 887-888. (SCIE)
Lin D, Yang HI*, Nguyen N, Hoang J, Kim Y, Vu V, Le A, Chaung K, Nguyen V, Trinh H, Li J, Zhang J, Hsing A, Chen CJ, Nguyen MH*, 2016, “Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.”, Alimentary pharmacology & therapeutics, 44(8), 846-855. (SCIE)
Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Chen CJ, 2016, “Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.”, HEPATOLOGY, 64(2), 381-389. (SCIE)
Hu HH, Liu J, Lin YL, Luo WS, Chu YJ, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, You SL, Yang HI*, Chen CJ, 2016, “The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.”, Gut, 65, 1514-1521. (SCIE)
Pan WC, Wu CD, Chen MJ, Huang YT, Chen CJ, Su HJ, Yang HI*, 2015, “Fine Particle Pollution, Alanine Transaminase, and Liver Cancer: A Taiwanese Prospective Cohort Study (REVEAL-HBV)”, JNCI-Journal of the National Cancer Institute, 108(3). pii: djv341. doi: 10.1093/jnci/djv341.. (SCIE)
Huang HC, Yang HI, Chou HC, Chen CY, Hsieh WS, Tsou KI, Tsao PN, 2015, “Preeclampsia and Retinopathy of Prematurity in Very Low-Birth-Weight Infants: A Population-based Study”, PLoS One, 10(11), e0143248 (co-1st author). (SCIE)
Liu J, Yang HI, Lee MH, Hsu WL, Chen HC, Chen CJ, 2015, “Epidemiology of virus infection and human cancer”, editor(s): Shurin MR, Thanavala Y, Ismail N, Infection and Cancer: Bi-Directorial Interactions, pp. 23-48, Switzerland: Springer International Publishing Switzerland.
Huang YT, Yang HI, Liu J, Lee MH, Freeman JR, Chen CJ, 2015, “Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk.”, EPIDEMIOLOGY, 27(1), 14-20. (SCIE, SSCI) (IF: 4.86; SCI ranking: 31.9%; SSCI ranking: 21.3%)
Hwai-I Yang*, Jessica Liu, Mei-Hsuan Lee, Hui-Han Hu, Chia-Ling Chang, Chien-Jen Chen, 2015, “Natural history of occult hepatitis B virus infection”, editor(s): Jean-Pierre Allain, Yongshui Fu, Chengyao Li, Giovanni Raimondo, Occult Hepatitis B Infection, pp. 1-21, Beijing, China: Science Press.
Liu J, Tseng TC, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Chen PJ, Chen CJ, Kao JH, 2015, “Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System.”, The Journal of infectious diseases, 211(10), 1566-1573. (SCIE)
Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'italien G, Chen CJ, 2014, “Development and Validation of a Clinical Scoring System for Predicting Risk of HCC in Asymptomatic Individuals Seropositive for Anti-HCV Antibodies.”, PloS one, 9(5), e94760. (SCIE)
Liu J, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Hsiao CK, Chen CJ, 2014, “Distinct Seromarkers Predict Different Milestones of Chronic Hepatitis B Progression.”, HEPATOLOGY, 60(1), 77-86. (SCIE)
Chen CJ, Hsu WL, Yang HI, Lee MH, Chen HC, Chien YC, You SL, 2014, “Epidemiology of virus infection and human cancer.”, Recent results in cancer research, 193, 11-32.
Chen CL, Yang WS, Yang HI, Chen CF, You SL, Wang LY, Lu SN, Liu CJ, Kao JH, Chen PJ, Chen DS, Chen CJ, 2014, “Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus infected carriers: a prospective study in Taiwan.”, CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 23(8), 1659-1671. (SCIE)
Yang HI*, Lee MH, Liu J, Chen CJ, 2014, “Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia.”, WORLD JOURNAL OF GASTROENTEROLOGY, 20(20), 6244-6251. (SCIE)
Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, Wang LY, You SL, Hsiao CK, Chen PJ, Chen CJ, 2014, “Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.”, Gut, 63(10), 1648-1657. (SCIE)
Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ, 2013, “A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.”, JOURNAL OF HEPATOLOGY, 58(5), 853-860. (SCIE)
Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ, Santella RM, 2013, “Global DNA methylation in a population with aflatoxin B1 exposure.”, Epigenetics, 8(9), 962-969. (SCIE)
Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, Kao JH, 2013, “Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients.”, PLoS One, 8(1), e53008. (SCIE)
Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ, 2013, “Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.”, PLoS One, 8(4), e61448. (SCIE)
Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ, 2013, “Prediction models of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles.”, HEPATOLOGY, 58(2), 546-554. (SCIE)
Yen TA, Yang HI, Hsieh WS, Chou HC, Chen CY, Tsou KI, Tsao PN, 2013, “Preeclampsia and the Risk of Bronchopulmonary Dysplasia in VLBW Infants: A Population Based Study.”, PloS one, 8(9), e75168. (SCIE)
Lin PH, Lin CC, Yang HI, Li LY, Bai LY, Chiu CF, Liao YM, Lin CY, Hsieh CY, Lin CY, Ho CM, Yang SF, Peng CT, Tsai FJ, Yeh SP, 2013, “Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3.”, LEUKEMIA RESEARCH, 37(3), 287-292. (SCIE)
Loomba R*, Yang HI*, Su J, Brenner D, Barrett-Connor E, Iloeje U, Chen CJ, 2013, “Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.”, AMERICAN JOURNAL OF EPIDEMIOLOGY, 177(4), 333-342. (SCIE)
Loomba R*, Liu J, Yang HI*, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ, 2013, “Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 11(12), 1636-1645.e1-3. (SCIE)
Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ, 2012, “Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.”, JOURNAL OF INFECTIOUS DISEASES, 206(4), 469-477. (SCIE)
Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC, 2012, “Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan.”, PLoS One, 7(4), e34779. (SCIE)
Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ, Santella RM, 2012, “Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested case-control study.”, CARCINOGENESIS, 33(7), 1340-1345. (SCIE)
Yang HI*, Hung HL, Lee MH, Liu J, Jen CL, Su J, Wang LY, Lu SN, You SL, Iloeje UH, Chen CJ, 2012, “Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 10(5), 527-534. (SCIE)
Huang HC, Yang HI, Chang YH, Chang RJ, Chen MH, Chen CY, Chou HC, Hsieh WS, Tsao PN, 2012, “Model to predict hyperbilirubinemia in healthy term and near-term newborns with exclusive breast feeding.”, Pediatrics and Neonatology, 53(6), 354-358. (SCIE)
Iloeje UH, Yang HI*, Chen CJ, 2012, “Natural history of chronic hepatitis B: what exactly has REVEAL revealed?”, LIVER INTERNATIONAL, 32(9), 1333-1341. (SCIE)
Chou HC, Chen MH, Yang HI, Su YN, Hsieh WS, Chen CY, Chen HL, Chang MH, Tsao PN, 2011, “211 G to a variation of UDP-glucuronosyl transferase 1A1 gene and neonatal breastfeeding jaundice.”, PEDIATRIC RESEARCH, 69(2), 170-174. (SCIE)
Wei SC, Ni YH, Yang HI, Su YN, Chang MC, Chang YT, Shieh MJ, Wang CY, Wong JM, 2011, “A hospital-based study of clinical and genetic features of Crohn's disease.”, JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 110(9), 600-606. (SCIE)
Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, Su J, Hsiao CK, Wang LY, You SL, Lu SN, Chen CJ, 2011, “Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.”, GASTROENTEROLOGY, 141(4), 1240-1248.e2. (SCIE)
Lee MH, Yang HI, Jen CL, Lu SN, Yeh SH, Liu CJ, You SL, Sun CA, Wang LY, Chen WJ, Chen CJ, 2011, “Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2.”, GUT, 60(5), 688-694. (SCIE)
Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ, 2011, “Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.”, JOURNAL OF CLINICAL ONCOLOGY, 29(27), 3643-3650. (SCIE)
Chen CJ, Yang HI, 2011, “Natural history of chronic hepatitis B REVEALed.”, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 26(4), 628-638. (SCIE)
Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK, 2011, “Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.”, LANCET ONCOLOGY, 12(6), 568-574. (SCIE)
Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ, 2010, “Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.”, GASTROENTEROLOGY, 138(5), 1747-1754. (SCIE)
Wang CH, Chen CJ, Lee MH, Yang HI, Hsiao CK, 2010, “Chronic hepatitis B infection and risk of atherosclerosis-related mortality: A 17-year follow-up study based on 22,472 residents in Taiwan.”, ATHEROSCLEROSIS, 211(2), 624-629. (SCIE)
Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, You SL, Chen WJ, Chen CJ, 2010, “Hepatitis C virus infection and increased risk of cerebrovascular disease.”, STROKE, 41(12), 2894-900. (SCIE)
Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ, Chen CJ, 2010, “Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study.”, JOURNAL OF CLINICAL ONCOLOGY, 28(30), 4587-4593. (SCIE)
Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, Chen CJ, 2010, “Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.”, GASTROENTEROLOGY, 139(2), 474-482. (SCIE)
Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, Chen CJ, 2010, “Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.”, JOURNAL OF CLINICAL ONCOLOGY, 28(14), 2437-2444. (SCIE)
Loomba R, Yang HI, Su J, Brenner D, Iloeje U, Chen CJ, 2010, “Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 8(10), 891-898.e1-2. (SCIE)
Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Lu SN, Chen CJ, 2010, “Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study.”, LIVER INTERNATIONAL, 30(3), 423-429. (SCIE)
Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM, 2009, “Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan.”, CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 18(3), 846-853. (SCIE)
Chen CJ, Yang HI, Iloeje UH, 2009, “Hepatitis B virus DNA levels and outcomes in chronic hepatitis B.”, HEPATOLOGY, 49(5 Suppl), S72-S84. (SCIE)
Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ, 2008, “Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.”, JNCI-Journal of the National Cancer Institute, 100(16), 1134-1143. (SCIE)
Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ, 2008, “Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.”, GASTROENTEROLOGY, 135(1), 111-121. (SCIE)
Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM, 2008, “Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan.”, CARCINOGENESIS, 29(5), 971-976. (SCIE)
Chen CJ, Iloeje UH, Yang HI, 2007, “Long-term outcomes in hepatitis B: the REVEAL-HBV study.”, Clinics in Liver Disease, 11(4), 797-816. (SCIE)
Wu HC, Wang Q, Wang LW, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM, 2007, “Polycyclic aromatic hydrocarbon- and aflatoxin-albumin adducts, hepatitis B virus infection and hepatocellular carcinoma in Taiwan.”, CANCER LETTERS, 252(1), 104-114. (SCIE)
Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI, Wang LY, Chen SY, Chen CJ, Santella RM, 2007, “Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA.”, CLINICAL CANCER RESEARCH, 13(8), 2378-2384. (SCIE)
Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Chen CJ, 2007, “Risk and predictors of mortality associated with chronic hepatitis B infection.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 5(8), 921-931. (SCIE)
Wu HC, Wang Q, Wang LW, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM, 2007, “Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan.”, CARCINOGENESIS, 28(5), 995-999. (SCIE)
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, 2006, “Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.”, GASTROENTEROLOGY, 130(3), 678-686. (SCIE)
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, 2006, “Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.”, JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295(1), 65-73. (SCIE)
You SL, Yang HI, Chen CJ, 2004, “Seropositivity of hepatitis B e antigen and hepatocellular carcinoma.”, ANNALS OF MEDICINE, 36(3), 215-224. (SCIE)
Wang LY, You SL, Lu SN, Ho HC, Wu MH, Sun CA, Yang HI, Chien-Jen C, 2003, “Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan.”, CANCER CAUSES & CONTROL, 14(3), 241-250. (SCIE)
Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ, 2002, “Hepatitis B e antigen and the risk of hepatocellular carcinoma.”, NEW ENGLAND JOURNAL OF MEDICINE, 347(3), 168-174. (SCIE)
Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS, 2001, “Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men.”, NEW ENGLAND JOURNAL OF MEDICINE, 345(26), 1877-1882. (SCIE)

Language